[go: up one dir, main page]

WO2007039761A3 - Crystal structure of cd44 and its use - Google Patents

Crystal structure of cd44 and its use Download PDF

Info

Publication number
WO2007039761A3
WO2007039761A3 PCT/GB2006/003734 GB2006003734W WO2007039761A3 WO 2007039761 A3 WO2007039761 A3 WO 2007039761A3 GB 2006003734 W GB2006003734 W GB 2006003734W WO 2007039761 A3 WO2007039761 A3 WO 2007039761A3
Authority
WO
WIPO (PCT)
Prior art keywords
crystal structure
protein
pharmaceuticals
tables
interaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2006/003734
Other languages
French (fr)
Other versions
WO2007039761A2 (en
Inventor
David G Jackson
Suneale Banerji
Martin Noble
Anthony J Day
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of WO2007039761A2 publication Critical patent/WO2007039761A2/en
Publication of WO2007039761A3 publication Critical patent/WO2007039761A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70585—CD44
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides the crystal structure of the CD44 protein molecule. The structure is set out in Tables 1 to 4. The structure may be used in to model the interaction of compounds such as pharmaceuticals with this protein, and to determine the structure of related molecules.
PCT/GB2006/003734 2005-10-06 2006-10-06 Crystal structure of cd44 and its use Ceased WO2007039761A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0520365.8A GB0520365D0 (en) 2005-10-06 2005-10-06 Crystal structure of CD44 and its use
GB0520365.8 2005-10-06

Publications (2)

Publication Number Publication Date
WO2007039761A2 WO2007039761A2 (en) 2007-04-12
WO2007039761A3 true WO2007039761A3 (en) 2007-06-21

Family

ID=35429941

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/003734 Ceased WO2007039761A2 (en) 2005-10-06 2006-10-06 Crystal structure of cd44 and its use

Country Status (2)

Country Link
GB (1) GB0520365D0 (en)
WO (1) WO2007039761A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012519710A (en) * 2009-03-06 2012-08-30 アングストロム プハルマセウトイカルス インコーポレイテッド Compositions and methods for modulating cell migration
CA2795698A1 (en) 2010-03-05 2011-09-09 Angstrom Pharmaceuticals, Inc. Modulation of intracellular signaling
EP4424711A3 (en) 2020-05-19 2024-10-23 Institut Curie Methods for the diagnosis and treatment of cytokine release syndrome

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003094843A2 (en) * 2002-05-10 2003-11-20 Incyte Corporation Cell adhesion and extracellular matrix proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003094843A2 (en) * 2002-05-10 2003-11-20 Incyte Corporation Cell adhesion and extracellular matrix proteins

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BANERJI SUNEALE ET AL: "LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan", THE JOURNAL OF CELL BIOLOGY, ROCKEFELLER UNIVERSITY PRESS, US, vol. 144, no. 4, 22 February 1999 (1999-02-22), pages 789 - 801, XP002159438, ISSN: 0021-9525 *
BLUNDELL T L ET AL: "HIGH-THROUGHPUT CRYSTALLOGRAPHY FOR LEAD DISCOVERY IN DRUG DESIGN", NATURE REVIEWS. DRUG DISCOVERY, NATURE PUBLISHING GROUP, BASINGSTOKE, GB, vol. 1, no. 1, January 2002 (2002-01-01), pages 45 - 54, XP009023187, ISSN: 1474-1784 *
HUMPHRIES M J ET AL: "The structure of cell-adhesion molecules.", TRENDS IN CELL BIOLOGY FEB 1998, vol. 8, no. 2, February 1998 (1998-02-01), pages 78 - 83, XP009079851, ISSN: 0962-8924 *
JACKSON DAVID GERALD ET AL: "Structure of the inflammatory homing receptor CD44 complexed with its pericellular matrix ligand hyaluronan.", FASEB JOURNAL, vol. 20, no. 5, Part 2, March 2006 (2006-03-01), & EXPERIMENTAL BIOLOGY 2006 MEETING; SAN FRANCISCO, CA, USA; APRIL 01 05, 2006, pages A915, XP009079901, ISSN: 0892-6638 *
TAKEDA MITSUHIRO ET AL: "Ligand-induced structural changes of the CD44 hyaluronan-binding domain revealed by NMR.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 29 DEC 2006, vol. 281, no. 52, 29 December 2006 (2006-12-29), pages 40089 - 40095, XP002422616, ISSN: 0021-9258 *
TERIETE PETER ET AL: "Structure of the regulatory hyaluronan binding domain in the inflammatory leukocyte homing receptor CD44.", MOLECULAR CELL 27 FEB 2004, vol. 13, no. 4, 27 February 2004 (2004-02-27), pages 483 - 496, XP002422615, ISSN: 1097-2765 *

Also Published As

Publication number Publication date
GB0520365D0 (en) 2005-11-16
WO2007039761A2 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
CO6180433A2 (en) LINGO LINK MOLECULES AND PHARMACEUTICAL USE OF THE SAME
ITRM20050332A1 (en) USE OF MOLECULES ABLE TO BLOCK TRKA'S ACTIVITY TO STRENGTHEN THE EFFECTS OF ANALGESIC OPPIACEI ON PAIN.
WO2008037380A3 (en) Alkyl benzoate mixtures
WO2004089396A3 (en) Anti-fungal peptidomimetics
WO2008155057A3 (en) Hydrocarbon mixture and use thereof
WO2006108861A3 (en) Solubility of cellulose in ionic liquids with addition of amino bases
WO2007038138A3 (en) Amido compounds and their use as pharmaceuticals
IL229509A0 (en) Compositions containing chemically modified small molecules and methods utilizing the same
WO2007100412A3 (en) Methods and compositions related to the modulation of riboswitches
WO2005105842A3 (en) Crystal structure of cytochrome p450 3a4 and uses thereof
MX2007011493A (en) Anti-inflammatory modalities.
WO2006079057A3 (en) Methods and compositions for specific inhibition of protein splicing by small molecules
WO2007039761A3 (en) Crystal structure of cd44 and its use
WO2006097327A3 (en) Soluble btnl2 protein useful to inhibit inflammatory disorders
WO2008017863A3 (en) Crystal structure of p53 mutants and their use
WO2007010285A3 (en) Crystal structure of human soluble adenylate cyclase
WO2009026053A3 (en) Inhibitors of iaspp interaction with an iaspp binding partner and methods of use
WO2006089954A3 (en) Compounds for stabilizing factor vii polypeptide formulations
DE602006018436D1 (en) GLEITMITTELZUBEREITUNG
WO2006113237A3 (en) Cd39l3 and its role in diabetes
UY29756A1 (en) DERIVATIVES OF 5-PIRIDAZINIL-1-AZABICICLO (3.2.1) OCTANO, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS.
ATE440832T1 (en) S-INDACENE AND INDENOÄ5,6-DÜÄ1,3ÜDIOXOL DERIVATIVES AND THEIR USE AS COMPONENTS OF LIQUID CRYSTALLINE MIXTURES
WO2004078776A3 (en) Ny-eso-1 peptides which bind to class ii molecules and uses thereof
Chyrva STRUCTURAL-SEMIOTIC APPROACH TO DEFINITION OF THE SYSTEM ARTISTIC AND PEDAGOGICAL KNOWLEDGE
TH84074B (en) Game console with portable LCD screen

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06794685

Country of ref document: EP

Kind code of ref document: A2